NEWS

AELMHU participates in the Conference on Designation, Development and Access to Orphan Medicines

AELMHU participates in the Conference on Designation, Development and Access to Orphan Medicines

On 20 September, the La Fe Hospital in Valencia hosted the Designation, Development and Access to Orphan Drugs Conference, organised by the Centre for Biomedical Research Network on Rare Diseases (CIBERER) and the Minority Diseases Platform.

The meeting provided a comprehensive overview of the entire process, explaining the steps required to obtain orphan drug designation and its benefits; the research and subsequent development of the drugs; the importance of continuity in researcher support; industry interest and patient involvement.

Manel Fontanet, from the Medicines Area of the Servei Català de la Salut; Julián Isla, patient representative on the EMA's Orphan Medicinal Products Committee and member of the CIBERER's External Scientific Advisory Committee; Arantxa Sancho, doctor specialising in clinical pharmacology at the Hospital Puerta del Hierro in Madrid; César Hernández, head of the Department of Medicines for Human Use of the Spanish Agency of Medicines and Health Products (AEMPS), Pascual Sanz, head of the U742 CIBERER group at the Institute of Biomedicine of Valencia-CSIC, and Regina Rodrigo, researcher of the U755 CIBERER at the Hospital La Fe of Valencia, and Josep Maria Espinalt, president of AELMHU, who dedicated his speech to the interest of the industry in this type of medicines.